Today, Insilico Medicine (“Insilico”), the clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announces its upcoming Summer Pharma.ai Updates webinar, scheduled for 10 a.m. ET on July 10. During the webinar, Founder and CEO Alex Zhavoronkov, PhD, will provide the latest company developments and introduce new features and applications of Insilico’s AI software suite, with a particular focus on the latest advancements in Biology42 and Chemistry42 through product demos, in-depth explanations, and real-world use cases. Ready for the future of Pharma.ai? Register here.

Researchers at the University of Tartu Institute of Genomics have gained a deeper understanding of why some people are more prone to experiencing side effects when taking antidepressants.

Researchers at the Max Planck Institute for Human Development have critically examined the basis for a frequently cited figure: that people make more than 200 unconscious decisions about food every day. This figure has circulated in scientific publications, the media, and health promotion campaigns for nearly 20 years without ever being empirically validated. An article published in the journal Appetite shows why a more nuanced view of eating behavior is needed.

In a significant step towards improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier system that delivers therapeutic antibodies directly to target antigens inside cancer cells. By utilizing a metal-polyphenol network, the system escapes endosomes, enabling intracellular targeting of antibodies, resulting in suppression of tumor growth and enhanced anti-cancer activity, offering a promising tool for targeted cancer therapy.